ASCO: ConcertAI uses real-world data to fill the research gap among patients excluded from NSCLC trials
NewsMedia Coverage
Through its real-world evidence collaboration with the FDA and the American Society of Clinical Oncology’s (ASCO’s) CancerLinQ data repository, ConcertAI has helped provide a peek into the performance of immune checkpoint inhibitors among a population of cancer patients who are frequently excluded from clinical trials.